Deadline: 03-Nov-2025
The Cytokinetics has announced the launch of its Communications Grant program, which will award five grants to patient advocacy organizations working with the hypertrophic cardiomyopathy (HCM) and heart failure communities.
The initiative is designed to strengthen outreach, awareness, and engagement by equipping organizations with resources to advance essential communications strategies.
The program aims to support advocacy groups in implementing new or critical initiatives that might otherwise be difficult to execute due to resource limitations. Funding can be used to bolster marketing and communications efforts or to support personnel activities, depending on the specific needs of each organization. By investing in these areas, the grants will help organizations expand their reach and amplify their impact on patient communities.
Eligible applicants include nonprofit or registered charitable organizations based in the United States, Canada, Europe, or the United Kingdom. All applicants must directly serve patients and families affected by HCM or heart failure. As part of the application process, organizations are required to submit a detailed proposal outlining how the grant funding would be applied and the expected impact of their communications activities.
Applications will undergo a thorough evaluation by a committee of Cytokinetics representatives. The selection process will prioritize proposals that demonstrate strong potential for outreach expansion, increased awareness, deeper community engagement, and measurable impact. Standard due diligence procedures will apply, including anti-bribery and anti-corruption compliance reviews.
Through this program, Cytokinetics underscores its commitment to empowering patient advocacy organizations that play a vital role in educating, supporting, and engaging the HCM and heart failure communities.
For more information, visit Cytokinetics.